Search

Displaying results 271 - 280 of 4265 in total
  1. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.

  2. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]

  3. Drug

    Umeclidinium

    go.drugbank.com/drugs/DB09076
    ApprovedInvestigational

    [A7719] By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. … [A7715] Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle.

  4. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acut...

  5. Drug

    Prolease-r-hFSH

    go.drugbank.com/drugs/DB05826
    Experimental

    Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.

  6. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  7. Drug

    AAV1-FS344

    go.drugbank.com/drugs/DB17855
    Investigational

    AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.

  8. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. … In December 2019, Ervebo was approved by the FDA in the United States.

  9. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  10. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    Both can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]